The biotech company Novavax, Inc. announced the start of its phase III study in Mexico and the United States, whose objective is to evaluate the efficacy of the vaccine NVX-CoV2373 against the disease of COVID-19. Said research will recruit up to 30 thousand volunteers, of legal age, in 115 different sites, globally. In particular, the study seeks to recruit two thousand volunteers in seven sites in the Mexican Republic, which will make it possible to collect data on the efficacy of the vaccine in our population.
States may buy covid vaccines
Foreign Minister Marcelo Ebrard used his Twitter account to share the news. Previous clinical trials have shown that the vaccine elicited a strong immune response against the virus and was well tolerated. The new Novavax study plans to recruit volunteers who belong to the demographic groups that have been most affected by the SARS-CoV-2 virus, as well as older adults or those with comorbidities.
After detailing the vaccine plan, López Obrador gives a message
The company appreciated the collaboration and participation of the Mexican government in this study, which will begin once the Federal Commission for the Protection against Sanitary Risks (Cofepris) grants its approval. The trust placed in Mexican health institutions is proof of their strength and commitment to scientific development.
The NVX-CoV2373 vaccine has been developed with support from the United States Government, which expressed its support for the Government of Mexico in accessing the vaccines developed in its country within the framework of President Andrés Manuel López Obrador’s visit to Washington DC, on July 8, 2020. The Government of Mexico reiterates its conviction: international cooperation is essential to face global problems.
Copyright law strictly prohibits copying all or part of Excelsior materials without first obtaining written permission and without including the link to the original text.